- Details
- Jonathan Chou discusses research on targeting CDK12-deficient prostate cancer with PARP inhibitors. Through analysis of CDK12 mutations, which occur in 5-8% of advanced prostate cancers, Dr. Chou demonstrates how different mutation types exhibit varying sensitivities to PARP inhibition. His work reveals that biallelic mutations show greater treatment response compared to monoallelic or gene rearra...
|
- Details
- Johann De Bono joins Andrea Miyahira to discuss his team's decade-long research on PARP inhibitor resistance in advanced prostate cancer, recently published in Cancer Cell. Drawing from extensive analysis of plasma samples and circulating tumor cells from the TOPARP trials, Dr. De Bono reveals that resistance primarily develops through restoration of homologous recombination repair function in BRC...
|
- Details
- Neal Shore and Sarah Young join Zachary Klaassen to discuss a JCO Oncology Practice publication advocating for universal germline genetic testing in prostate cancer patients. The discussion highlights that 8-14% of unselected prostate cancer patients carry pathogenic variants, with clinical utility across all disease stages from early detection to treatment selection. Despite the proven benefits f...
|
- Details
- Neeraj Agarwal discusses a JAMA Network Open study examining physicians' reasons for or against treatment intensification in metastatic prostate cancer. The study surveys 107 US physicians managing over 600 patients, revealing significant underutilization of combination therapies despite strong evidence supporting their use. Key barriers include concerns about side effects, quality of life impact,...
|
- Details
- George Zhao joins Andrea Miyahira to discuss research examining three-dimensional genome organization in metastatic prostate cancer. The study integrates multi-omic data including RNA-seq, whole-genome sequencing, and Hi-C sequencing. Their key finding reveals that approximately one-third of samples show disrupted genomic organization around the androgen receptor (AR) gene, which they discover is...
|
- Details
- Andrea Miyahira speaks with Geraldine Gueron and Agustina Sabater about a paper on neuroendocrine prostate cancer. The discussion focuses on the development of a seven-gene stemness signature that predicts cancer progression. Using machine learning algorithms and multiple data sets, they create a risk-score model that shows significant prognostic value across different stages of prostate cancer, i...
|
- Details
- Christian Gratzke discusses the Phase III trial of opevesostat, a CYP11A1 inhibitor, for metastatic castration-resistant prostate cancer (mCRPC). The study examines opevesostat's unique mechanism of targeting androgen biosynthesis upstream of current treatments, potentially offering more complete testosterone suppression than existing therapies. The ongoing 1,500-patient trial compares opevesostat...
|
- Details
- Oliver Sartor discusses the ProstACT GLOBAL trial design, examining TLX591, a PSMA-targeting antibody bound to lutetium-177 for metastatic castration-resistant prostate cancer treatment. The phase III trial includes a 30-patient safety lead-in followed by a 400-patient randomized study comparing standard of care (ARPI switch or docetaxel) with or without TLX591. Unlike other PSMA-targeted therapie...
|
- Details
- Diane Newman discusses with Kristine Talley the RESTORE study examining urinary incontinence symptoms in gay and bisexual prostate cancer survivors, marking the first comprehensive examination of this understudied population. The research, funded by the National Cancer Institute, analyzes data from 400 men with a mean age of 63.5 years, revealing that 43% experience daily incontinence. While the t...
|
- Details
- Neeraj Agarwal discusses FOXA1 alterations in prostate cancer with Emmanuel Antonarakis and Justin Hwang, exploring research that identifies FOXA1 mutations in 15% of prostate cancers, with higher prevalence in Asian (25%) and Black (20%) patients. Their Minnesota classification system reveals that different FOXA1 mutations can lead to opposing clinical outcomes: some variants enhance hormone sens...
|
